产品矩阵再添新品类 方盛制药深耕中药创新药领域

Core Insights - The launch of "Yangxue Qufeng Zhitong Granules" marks a significant breakthrough for the company in the field of traditional Chinese medicine, filling a clinical gap for frequent tension-type headaches [1][2] - The product is expected to tap into a market worth over 100 billion yuan, with a patient population of 285 million in China suffering from tension-type headaches [2][3] Product Development and Market Strategy - The company has invested approximately 27 million yuan in the development of the new product, which received its drug registration certificate in June 2025 [2] - The granules have been included in the 2025 medical insurance directory, providing a solid foundation for market promotion and sales growth [2] - The company aims to cover over 500 public medical institutions and exceed the first-year sales revenue of its previous innovative product, Xuanqi Jiangu Pian, by 2026 [3] R&D and Innovation - The company has a strong focus on R&D, with 32 approved 1.1 category innovative traditional Chinese medicines in the past decade, of which three are from the company [3][4] - There are nearly 20 ongoing innovative traditional Chinese medicine projects, with three 1.1 category new drugs entering clinical stages [3] Future Growth Plans - The company plans to accelerate the development of its research pipeline over the next three years, aiming to transition from a follower to a leader in traditional Chinese medicine [4] - The goal is to create multiple products with annual sales of 300 million to 500 million yuan, ensuring steady growth in performance [4] - The company is also preparing for policy changes and new growth points by focusing on high-threshold generic drugs and enhancing its innovative drug output [4]